Cancer researchers had worried that President Donald Trump might choose an unconventional candidate to replace Harold Varmus as director of the National Cancer Institute in Bethesda, Maryland. But his choice, announced in June 2017, allayed their fears. Norman "Ned" Sharpless, who was then director of the Lineberger Comprehensive Cancer Center at the University of North Carolina in Chapel Hill, checked all the right boxes for the community: He is a physician-scientist who treats patients, he has started two biotech companies, and he runs a basic research lab. In an interview last month, Sharpless declined to lay out specific plans for the $5.7 billion institute. But he stressed three areas: big data, basic research, and translating discoveries into devices and treatments.

中文翻译：

---

癌症研究所负责人吹捧大数据和基础研究

癌症研究人员曾担心，唐纳德·特朗普总统可能会选择一位非常规候选人来接替哈罗德·瓦穆斯 (Harold Varmus) 担任马里兰州贝塞斯达国家癌症研究所所长。但他于 2017 年 6 月宣布的选择减轻了他们的恐惧。Norman "Ned" Sharpless 当时是北卡罗来纳大学教堂山分校 Lineberger 综合癌症中心的主任，他为社区检查了所有正确的框：他是一名治疗患者的医生科学家，他已经开始了两项生物技术公司，他经营着一个基础研究实验室。在上个月的一次采访中，Sharpless 拒绝为这家价值 57 亿美元的研究所制定具体计划。但他强调了三个领域：大数据、基础研究以及将发现转化为设备和治疗方法。